Executive Brief: Cannabis Rescheduling Probability and Timing Under the Trump Administration
Summary of Probability & Timing Assessment
Likelihood of Rescheduling in Current Term:
Based on a comprehensive inventory of statements and actions, there is a high probability (approximately 70%) that President Trump’s administration will move to reschedule cannabis to Schedule III during the current term. This assessment weighs Trump’s explicit campaign promise to pursue Schedule III rescheduling and related reforms against mixed signals from his administration and political headwinds. While President Trump endorsed rescheduling on the 2024 campaign trail and signaled support for medical cannabis initiatives, execution has been cautious since taking office. Key officials have so far paused formal action, reflecting both procedural inertia and strategic timing considerations. Overall, however, the balance of signals – including Trump’s own words, industry influence, and historical norms – indicates he is more likely than not to follow through with rescheduling in some form this term.
Most Likely Announcement Window:
We forecast that a formal announcement of cannabis being moved to Schedule III is most likely in Q1 2026, with earliest plausible timing in late 2025 and latest by mid-2027. The current base case is an announcement by March 2026, likely timed after ongoing administrative reviews and political groundwork are completed.
- Earliest Plausible: December 2025 – If President Trump decides to capitalize on momentum from recent positive signals (e.g., his late September pro-medical cannabis post), an announcement could come by year-end 2025. This would likely occur if internal deliberations conclude quickly and the White House opts for a decisive win heading into 2026.
- Latest Plausible: Mid-2027 – A delay beyond 2026 could occur if opposition within the administration or Congress stalls the process. Given the 2028 election cycle, an announcement later than 2027 is unlikely; if rescheduling is not announced by then, it may effectively be shelved barring a political shift. Our 90% confidence window for an announcement is Q4 2025 through Q4 2026, reflecting uncertainty in Trump’s decision cadence and regulatory pacing.
Top Risk Factors:
The chief risks to a timely rescheduling are political and bureaucratic. Internally, some Trump advisors express skepticism or outright opposition – e.g. former aide Sean Spicer insists Trump’s personal “no drugs” philosophy could inhibit action, and Transportation Secretary Sean Duffy has publicly argued against rescheduling, citing addiction and safety concerns. Externally, congressional Republicans have moved to block rescheduling through budget riders (Section 607 in the House FY26 appropriations bill) that would prohibit DOJ from using funds to implement Schedule III. Additionally, voices like Dr. Ben Carson (former HUD Secretary) urge caution by highlighting purported links between cannabis and crime. These factors could slow or derail the effort if President Trump becomes convinced of political downsides.
Investor-Relevant Triggers:
- White House Signals: Presidential communications remain the primary catalyst. A definitive statement from Trump (e.g. in a press briefing or social media) that he has directed rescheduling to proceed would immediately trigger a market rally in cannabis equities. Conversely, prolonged silence or negative comments (e.g. emphasizing “it’s a very complicated subject” without action) would dampen expectations.
- Regulatory Milestones: Any movement in the DEA’s formal rulemaking docket – such as scheduling of the postponed rescheduling hearings or publication of a final rule in the Federal Register – will be a strong indicator. An instruction by Attorney General Pam Bondi or DEA Administrator Terrance Cole to resume or conclude the hearing process would suggest impending action. In contrast, continued stalling in the DEA’s 90-day status reports (which so far note “no progress” each quarter) points to delay.
- Political Developments: Watch for congressional signals. If the Senate removes the House rider blocking rescheduling (as expected) and key GOP figures back off public criticism, the path for announcement is clearer. Conversely, if anti-rescheduling factions double down – e.g. holding hearings to oppose the HHS recommendation or attaching riders in final spending bills – it may indicate Trump acquiescing to stall tactics.
Investor Positioning:
Given the current information, investors should be positioned for a base-case announcement in early-to-mid 2026 with upside optionality for an earlier move. The recent surge in cannabis stock prices following Trump’s positive signals (e.g. a 25%+ jump in U.S. cannabis ETF value after his late September video post) underscores the market’s sensitivity to White House messaging. However, the prospect of choppy implementation – including potential delays or partial measures – means portfolios should hedge for scenario volatility.
Structured Signal Book: Key Statements & Signals on Cannabis Rescheduling
The following table inventories verifiable statements and positions from President Trump and relevant officials regarding rescheduling cannabis to Schedule III. Each entry includes the source, role, a summary or quote, the date, stance (supportive, opposed, or ambiguous), specificity of the commitment, and any procedural context or “hook” mentioned. Archive and source links are provided for due diligence.
Credibility scoring: Primary statements (direct quotes, official posts) are highest credibility; second-hand reports are noted as lower specificity.
| Source / Role | Statement (Summary / Quote) | Date | Stance | Specificity & Procedural Hook | Reference |
|---|---|---|---|---|---|
| Donald Trump – Candidate (Truth Social) | “As I have previously stated, I believe it is time to end needless arrests… As a Floridian, I will be voting YES on Amendment 3… As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking.” — Endorses FL legalization; promises federal rescheduling and banking reform | Sept 9, 2024 | Strongly Supportive | Explicit campaign pledge — Commits to Schedule III rescheduling (“Schedule 3 drug”) and related reforms; concrete policy tie-ins. | Truth Social post (via Reuters) |
| Donald Trump – Candidate (Interview remark) | Indicated he was open to legalizing adult-use cannabis in FL, foreshadowing support for Amendment 3. | Late Aug 2024 | Supportive | Informal but positive; evolving position. | Reuters campaign coverage |
| Donald Trump – President (Private fundraiser) | Told donors he is “interested” in reclassifying marijuana to Schedule III and will consider the change after being lobbied by a cannabis CEO. | Early Aug 2025 | Supportive (privately) | Tentative commitment — Acknowledged paused proposal and intent to revisit. | WSJ/Reuters |
| Donald Trump – President (Press Briefing) | “Some people like it, some people hate it… It does bad for the children… It’s a very complicated subject… We’re looking at reclassification, and we’ll make a determination over the next… few weeks.” | Aug 11, 2025 | Ambiguous/Mixed | Near-term timeline; balanced positives/concerns; first on-record confirmation as President. | WH Briefing (IVN/CBT) |
| Donald Trump – President (Truth Social post) | Shared a video praising CBD’s medical benefits; implied support for integrating cannabis into healthcare. | Sept 28, 2025 | Supportive (Medical) | Implied endorsement; viewed as a trial balloon ahead of action. | IVN / Truth Social |
| Pam Bondi – Attorney General | Past anti-cannabis stance; in 2025 hearings said DOJ will “look at” specific programs; received GOP letter urging rejection of Schedule III. | 2025 | Skeptical/Opposed | Non-committal; DOJ has effectively paused process; political pressure noted. | Senate Q&A; GOP letter |
| Terrance Cole – DEA Administrator | Dodged commitment in confirmation; later no public moves; DEA filings confirm process remains pending with no progress. | Jul–Oct 2025 | Skeptical / Following Orders | Inaction signals awaiting White House direction; DEA historically defers to HHS science. | CBT; DEA status report |
| Sara Carter – ONDCP (Nominee) | Personally pro-medical in 2023; in 2025 hearings stayed neutral and process-focused; pledged to examine evidence. | Sep–Oct 2025 | Neutral (Constrained) | No explicit support; deference to HHS/FDA science; ONDCP cannot advocate legalization of Schedule I. | Senate Judiciary QFR (CBT) |
| Xavier Becerra – HHS Secretary (Biden) | HHS recommended Schedule III on Aug 29, 2023; key scientific input binding in practice. | Aug 29, 2023 | Supportive (Official) | Definitive scientific finding; procedural linchpin for DEA action. | HHS letter / DOJ release |
| Ben Carson – Former HUD Secretary | Op-ed urging caution; linked marijuana to crime; counseled Trump to avoid fueling harm. | Sep 13, 2025 | Opposed (Safety Concern) | Influences conservative base; does not alter procedure directly. | Fox News op-ed (via BIPC) |
| Roger Stone – Trump Advisor | Advocated rescheduling; framed Schedule III as a critical next step; argued public support is strong. | Sep 2025 | Strongly Supportive | Informal lobbying signal within Trump’s orbit. | Marijuana Moment op-ed |
| Sean Spicer – Former Press Secretary | Said he’s not convinced Trump will act; emphasized Trump’s “no drugs” personal credo. | Sep 2025 | Opposed (Personal) | Commentary reflecting social conservative skepticism. | Spicer Show (BIPC) |
| House Republicans | Appropriations rider (Sec. 607) to bar DOJ funds for rescheduling/descheduling; letters urging AG to reject Schedule III. | Aug–Sep 2025 | Opposed | Legislative barrier; may be stripped in conference; key tripwire for timing. | Marijuana Moment; BIPC |
| Pro‑reform Republicans | Rep. Greg Steube to reintroduce bill moving cannabis to Schedule III after Trump’s comments. | 2024–25 | Supportive | Legislative backup; signals bipartisan opening. | CBT |
| Federal Regulators (DOJ/OIRA) | OLC memo supports DEA authority; NPRM published May 21, 2024; hearing noticed Aug 29, 2024; process paused since Jan 2025. | May 2024 – Oct 2025 | Neutral (Process) | Docket exists; finalization awaits White House/DOJ direction. | DOJ OPA; Federal Register |
Notes: Table compiled from verified public sources. “Procedural hook” highlights mentions of formal process (rulemaking, hearings, legal standards) indicating ties to the rescheduling timeline. Credibility: High for direct quotes from principals; medium for reported private remarks.
Process Status One-Pager (As of Oct 15, 2025)
Regulatory Docket: The rescheduling effort is mid-process but stalled. Key elements under the CSA:
- HHS Scientific Review — Completed: HHS delivered its evaluation Aug 29, 2023 recommending Schedule III.
- DOJ/DEA Proposed Rule — Completed: NPRM published May 21, 2024 (Docket DEA-2024-0059).
- Administrative Hearing — Initiated then Paused: Hearing noticed Aug 29, 2024; convened preliminarily Dec 2, 2024; stayed pending interlocutory appeal; no progress through Oct 2025.
- OIRA Review: Initial NPRM cleared; no final rule submitted as of Oct 2025; listed as long-term action.
- Federal Register Notices: NPRM (89 FR 34743) and Notice of Hearing (89 FR 70148) published; no final rule yet.
- Judicial/Legal Environment: OLC memo provides legal backbone for Schedule III; litigation risk exists either way.
Summary: The ball is in the Trump administration’s court. All preliminary steps are complete or resumable. A final decision by AG Bondi/DEA Admin Cole—aligned with White House direction—can trigger publication at any time.
Current Status (Oct 2025): No formal announcement yet; cannabis remains Schedule I; process frozen pending a high-level decision.
Scenario Table: Rescheduling Outcomes, Likelihood, and Implications
| Scenario | Likelihood | Implications for Policy & Industry | Key Tripwires to Monitor |
|---|---|---|---|
| 1. On-Time Announcement (Schedule III in 2026) Trump follows through relatively promptly |
~60% (Base case) |
Description: Announcement by early 2026 (Q1/Q2). Regulatory Impact: Final rule in 2026; effective soon after. Industry Effects: 280E relief; likely equities rally. Political Impact: Claimable bipartisan win. |
DEA docket activity (hearing rescheduled/canceled); White House/AG announcement; Senate strips House rider; OLC/DOJ leak hints; lobby signals. |
| 2. Delayed/Conditional Rescheduling “Wait and See” – slow roll or tied to other reforms |
~25% |
Description: Decision slips to late 2026/2027; hearings resume first. Regulatory Impact: ALJ process runs; final decision late 2026/27. Industry Effects: Volatility; continued 280E burden. Political Impact: Balancing act; issue lingers. |
Continued silence; mixed rhetoric; linkage to SAFE Banking; Rider persists; litigation cues. |
| 3. Stall or No Rescheduling Reversal or indefinite shelf |
~15% |
Description: No action this term; NPRM withdrawn/expires. Regulatory Impact: Status quo Schedule I remains. Industry Effects: Negative; funding/tax headwinds continue. Political Impact: Promise unfulfilled; appeals to social conservatives. |
Explicit rejection by WH/AG; Hardline appointments; Rider enacted and accepted; Late-cycle tough-on-drugs rhetoric. |
Timing Forecast Model: Timeline Estimate and Milestones
We combine base-rate durations for DEA scheduling actions with case-specific signals. Process milestones:
- Initiation (Completed): HHS review request (Oct 2022) → HHS recommendation (Aug 2023).
- Rule Proposal (Completed): NPRM published (May 2024).
- Comment & Hearing Phase (In progress): NPRM (May 2024) → Comments (Summer 2024) → Hearing set (Dec 2024).
- Pause (Political Reset): Jan–Oct 2025 — no action.
Option A: Expedited Finalization. White House directs DEA to issue a Final Rule without further hearings; OIRA review in 60–90 days; announcement by March 2026.
Option B: Resume Hearings. ALJ hearing in early 2026; recommended decision mid/late 2026; final rule late 2026 or early 2027.
Confidence Window: 90% interval for announcement: Q4 2025 – Q4 2026; median around Spring 2026.
Key Milestone Timeline (projected):
- Late 2025: Decision-making phase; watch for preparatory moves and messaging.
- Q1 2026: Announcement & Final Rule publication (expedited track).
- Q2 2026: Effective date hits; implementation; market/industry reactions.
- Mid–Late 2026: (If slow track) ALJ recommendation, then final rule.
Methodology and Source Index
Methodology: Deep-research aggregation of campaign/admin statements, regulatory dockets, and official actions as of Oct 15, 2025. Prioritized primary sources and aligned with CSA/OIRA processes. Probability estimate reflects HHS recommendation weight, presidential incentives, and opposition strength.
Credibility: Primary docs (press releases, FR notices, direct quotes) weighted highest; reputable reporting corroborated. Dataset fields captured role, date, stance, specificity, and procedural hooks for each signal.
Key Sources (selected):
- Reuters – Trump supports FL legalization & pledges Schedule III
- MJBizDaily – Market reaction to Trump post
- IVN – Trump shares pro-cannabis video
- Cannabis Business Times – ONDCP nominee sidesteps Qs; DEA admin hearing
- DOJ OPA – NPRM submitted (May 16, 2024)
- Federal Register – Notice of Hearing (Aug 29, 2024)
- Buchanan Ingersoll & Rooney – Rescheduling update (Carson, Stone; GOP letters)
- Marijuana Moment – House rider; GOP commentary
Leave a Reply